Stocksigma LogoStocksigma Logo

Anupam Rasayan Reports Strong Q2FY27 Results and Strategic Pharma Expansion

Anupam Rasayan delivered record consolidated Q2FY27 revenue of ₹821 Cr, up 23% QoQ and 11% YoY. Consolidated EBITDA rose 41% YoY (16% QoQ) to ₹202 Cr

Anupam Rasayan Reports Strong Q2FY27 Results and Strategic Pharma Expansion

Anupam Rasayan India Ltd · Investor Presentation · 06 Nov 2026, 9:33 pm

Anupam Rasayan Reports Strong Q2FY27 Results and Strategic Pharma Expansion Anupam Rasayan delivered record consolidated Q2FY27 revenue of ₹821 Cr, up 23% QoQ and 11% YoY. Consolidated EBITDA rose 41% YoY (16% QoQ) to ₹202 Cr, expanding margins to 25% from 19%, driven by high-margin performance materials and pharmaceuticals. PAT grew 14% YoY (27% QoQ) to ₹65 Cr. H1FY27 consolidated revenue reached ₹1,489 Cr (+21% YoY) with EBITDA of ₹377 Cr (+38% YoY). Strategically, the company completed a 50.07% controlling acquisition of Bliss GVS Pharma on 28th Sep'26 and signed a six-year US specialty metal supply contract.

Original exchange filing (PDF)

More announcements from Anupam Rasayan India Ltd

All Anupam Rasayan India Ltd announcements